Biography and Research Information
OverviewAI-generated summary
Spencer Parnell's research focuses on the treatment of SARS-CoV-2 infections in an outpatient setting. His work has investigated the comparative efficacy of different administration routes for monoclonal antibody therapies. Specifically, his recent publication examined the noninferiority of subcutaneous versus intravenous administration of casirivimab/imdevimab for treating outpatients with SARS-CoV-2.
Parnell collaborates with researchers from the University of Arkansas for Medical Sciences and the University of Arkansas at Fayetteville. His scholarly output includes one publication with one citation, and he has an h-index of 1. He is recently active in research, with his most recent publication dating to 2022.
Metrics
- h-index: 1
- Publications: 1
- Citations: 1
Selected Publications
-
Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting (2022)
Collaboration Network
Top Collaborators
Alex Belote
University of Arkansas for Medical Sciences (US)
1 shared publication
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Sharon Reece
University of Arkansas for Medical Sciences
1 shared publication
In database
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Samantha Robinson
University of Arkansas at Fayetteville
1 shared publication
In database
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Hanna Jensen
University of Arkansas for Medical Sciences (US)
1 shared publication
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Sheena CarlLee
University of Arkansas for Medical Sciences
1 shared publication
In database
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Megan Clark
University of Arkansas for Medical Sciences (US)
1 shared publication
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Caroline G. Geels
University of Arkansas for Medical Sciences
1 shared publication
In database
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
James Newton
1 shared publication
- Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
Similar Researchers
Based on overlapping research topics
Z. Chauhan
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Pharmacological Effects and Toxicity Studies
Catherine Sabith
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Emergency and Acute Care Studies
Jessica Thrush
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Pharmacological Effects and Toxicity Studies
M. Kathryn Allison
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Emergency and Acute Care Studies
Dean W. Roberts
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Pharmacological Effects and Toxicity Studies
Joel Mosley
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Pharmacological Effects and Toxicity Studies